[{"id":"64b32301-3f36-4fa1-99fc-4f512b0b9e43","acronym":"","url":"https://clinicaltrials.gov/study/NCT00826150","created_at":"2021-01-18T03:08:32.308Z","updated_at":"2024-07-02T16:36:58.906Z","phase":"Phase 1/2","brief_title":"Phase 1/2a Study of DTA-H19 in Advanced Stage Ovarian Cancer","source_id_and_acronym":"NCT00826150","lead_sponsor":"Anchiano Therapeutics Israel Ltd.","biomarkers":" H19","pipe":"","alterations":" ","tags":["H19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e inodiftagene vixteplasmid (BC 819)"],"overall_status":"Completed","enrollment":" Enrollment 14","initiation":"Initiation: 06/01/2009","start_date":" 06/01/2009","primary_txt":" Primary completion: 02/01/2012","primary_completion_date":" 02/01/2012","study_txt":" Completion: 02/01/2012","study_completion_date":" 02/01/2012","last_update_posted":"2019-06-13"},{"id":"c1dc8724-8c28-46dc-84a4-74bea6e56812","acronym":"","url":"https://clinicaltrials.gov/study/NCT00595088","created_at":"2021-01-18T02:12:12.208Z","updated_at":"2024-07-02T16:37:00.046Z","phase":"Phase 2b","brief_title":"Phase 2b, Trial of Intravesical DTA-H19/PEI in Patients With Intermediate-Risk Superficial Bladder Cancer","source_id_and_acronym":"NCT00595088","lead_sponsor":"Anchiano Therapeutics Israel Ltd.","biomarkers":" H19","pipe":"","alterations":" ","tags":["H19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e inodiftagene vixteplasmid (BC 819)"],"overall_status":"Completed","enrollment":" Enrollment 47","initiation":"Initiation: 01/01/2008","start_date":" 01/01/2008","primary_txt":" Primary completion: 01/01/2013","primary_completion_date":" 01/01/2013","study_txt":" Completion: 01/01/2013","study_completion_date":" 01/01/2013","last_update_posted":"2019-04-30"},{"id":"3f865f0a-83d2-44a9-9a7e-64c608194e5b","acronym":"","url":"https://clinicaltrials.gov/study/NCT00711997","created_at":"2021-01-18T02:39:51.495Z","updated_at":"2024-07-02T16:37:01.512Z","phase":"Phase 1/2","brief_title":"Phase 1/2a DTA-H19 in Patients With Unresectable Pancreatic Cancer","source_id_and_acronym":"NCT00711997","lead_sponsor":"Anchiano Therapeutics Israel Ltd.","biomarkers":" H19","pipe":"","alterations":" ","tags":["H19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e inodiftagene vixteplasmid (BC 819)"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 08/01/2009","start_date":" 08/01/2009","primary_txt":" Primary completion: 10/01/2010","primary_completion_date":" 10/01/2010","study_txt":" Completion: 12/01/2010","study_completion_date":" 12/01/2010","last_update_posted":"2019-03-20"}]